Panda Vandana, Deshmukh Amol, Singh Sneha, Shah Taasin, Hingorani Lal
Department of Pharmacology & Toxicology, Prin. K. M. Kundnani College of Pharmacy, Jote Joy Building, Rambhau Salgaonkar Marg, Cuffe Parade, Colaba, Mumbai, 400005, India.
Pharmanza Herbals Pvt. Ltd., Plot No. 214, Near Vadadla Patiya, Borsad-Tarapur Road, Kaniya, Anand, GJ, 388435, India.
J Ayurveda Integr Med. 2021 Jul-Sep;12(3):506-513. doi: 10.1016/j.jaim.2021.05.005. Epub 2021 Aug 8.
Nishamalaki is an Ayurvedic herbal formulation used to treat type 2 diabetes mellitus (T2DM), comprises Emblica officinalis and Curcuma longa.
OBJECTIVE(S): One of the main cause of T2DM is Insulin Resistance (IR) hence, this study was planned to evaluate IR lowering effect of a standardized Nishamalaki extract "EmbliQur" in high-fat diet (HFD) and streptozotocin (STZ) induced T2DM rats.
Curcuminoids (23.89% w/w), gallic acid (5.27% w/w) and tannins (25.44% w/w) were quantified from EmbliQur. Rats were fed HFD throughout the study of 45 days and received STZ (40 mg/kg, i.p) on the 15th day of the study. Rats with more than 250 mg/dl of fasting blood glucose level (FBGL) were considered diabetic and selected for administration of EmbliQur (500 mg and 1000 mg/kg) or the standard drug metformin (120 mg/kg, p.o) from the 18th day of the study for the next 27 days. FBGL and insulin levels of all rats were measured weekly and an oral glucose tolerance test (OGTT) was done at the end of the study. The values of FBGL and insulin were used to calculate IR by the HOMA-IR, QUICKI and Matsuda methods.
Rats treated with STZ/HFD had significantly higher than normal FBGL and insulin levels throughout the study and exhibited skewed IR indices in the above three methods of IR assessment. EmbliQur treatment successfully lowered the HFD/STZ-elevated BGL and insulin levels, and ameliorated IR in all models of IR evaluation.
EmbliQur 1000 mg/kg was noted to be more effective than EmbliQur 500 mg/kg in alleviating IR.
尼沙玛拉基是一种用于治疗2型糖尿病（T2DM）的阿育吠陀草药配方，由余甘子和姜黄组成。
T2DM的主要病因之一是胰岛素抵抗（IR），因此，本研究旨在评估标准化的尼沙玛拉基提取物“EmbliQur”对高脂饮食（HFD）和链脲佐菌素（STZ）诱导的T2DM大鼠的IR降低作用。
对EmbliQur中的姜黄素类（23.89% w/w）、没食子酸（5.27% w/w）和单宁（25.44% w/w）进行定量。在为期45天的研究中，大鼠全程喂食HFD，并在研究的第15天接受STZ（40 mg/kg，腹腔注射）。空腹血糖水平（FBGL）超过250 mg/dl的大鼠被视为糖尿病大鼠，并从研究的第18天起选择给予EmbliQur（500 mg和1000 mg/kg）或标准药物二甲双胍（120 mg/kg，口服），持续27天。每周测量所有大鼠的FBGL和胰岛素水平，并在研究结束时进行口服葡萄糖耐量试验（OGTT）。FBGL和胰岛素值用于通过HOMA-IR、QUICKI和松田方法计算IR。
在整个研究过程中，用STZ/HFD处理的大鼠的FBGL和胰岛素水平显著高于正常水平，并且在上述三种IR评估方法中表现出偏态的IR指数。EmbliQur治疗成功降低了HFD/STZ升高的血糖水平和胰岛素水平，并改善了所有IR评估模型中的IR。
在减轻IR方面，1000 mg/kg的EmbliQur比500 mg/kg的EmbliQur更有效。
